License Agreement with Duke - Additional Information (Detail) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 03, 2023 |
Feb. 28, 2025 |
Nov. 30, 2023 |
Nov. 30, 2021 |
|
| Patent Option And Technology License Agreement [Line Items] | ||||
| Impairment of assets | $ 13,108,064 | |||
| Duke University [Member] | ||||
| Patent Option And Technology License Agreement [Line Items] | ||||
| Amount on excess damages | $ 100,000,000 | |||
| Milestone payments first phase III clinical trial | $ 2,000,000 | |||
| Capitalized costs to obtain agreement | $ 15,372,382 | |||
| Capitalized costs amortization period | 16 years | |||
| Duke University [Member] | Maximum [Member] | ||||
| Patent Option And Technology License Agreement [Line Items] | ||||
| Additional capital related to research | $ 350,000 | |||
| Research Agreement [Member] | ||||
| Patent Option And Technology License Agreement [Line Items] | ||||
| Consideration payable for research | $ 187,400 | |||
| X | ||||||||||
- Definition Additional capital related to research. No definition available.
|
| X | ||||||||||
- Definition Amount on excess damages. No definition available.
|
| X | ||||||||||
- Definition The amount of consideration payable for research No definition available.
|
| X | ||||||||||
- Definition Milestone payments. No definition available.
|
| X | ||||||||||
- Definition Patent option and technology license agreement. No definition available.
|
| X | ||||||||||
- Definition Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount recognized as an operating expense or loss during the period to reduce the carrying amount of a project that has been impaired but not abandoned. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|